# solid tumors FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/solid-tumors

> 7 upcoming FDA catalysts in solid tumors: biologics (HCWB) on 1H 2027 (trial start); Krazati (adagrasib, BMY) on Feb to May 2028 (topline data readout); Krazati (adagrasib, BMY) on February 2028 (primary completion); navlimetostat (BMY) on Aug to Nov 2028 (topline data readout); and 3 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, half-year only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for solid tumors?

7 upcoming FDA catalysts in solid tumors: biologics (HCWB) on 1H 2027 (trial start); Krazati (adagrasib, BMY) on Feb to May 2028 (topline data readout); Krazati (adagrasib, BMY) on February 2028 (primary completion); navlimetostat (BMY) on Aug to Nov 2028 (topline data readout); and 3 more. SEC Form 10-K: "Based on promising data seen in preclinical in-vitro and in-vivo studies conducted by HCW Biologics, Trimmune expects to initiate a Phase 1 clinical trial in China in the first half of 2027 to evaluate HCW11-006 in the treatment of solid tumors." [Calendar and source filings](https://sec-api.dev/indications/solid-tumors)

Source: SEC Form 10-K, accession 0001193125-26-134934, https://www.sec.gov/Archives/edgar/data/1828673/000119312526134934/hcwb-20251231.htm (retrieved 2026-11-12). Last confirmed 2026-03-31. Cite: https://sec-api.dev/indications/solid-tumors#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 29, 2025 | [PSV359 trial start](https://sec-api.dev/pdufa/psv359) | CATX | solid tumors | completed | "On April 29, 2025, Perspective Therapeutics, Inc. issued a press release announcing that the first patient was dosed with [212Pb]PSV359 in a Phase 1/2a dose-finding trial to determine the safety and preliminary anti-tumor activity of the radiopharmaceutical [212Pb]PSV359 in patients with solid tumors that express fibroblast activation protein alpha." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/728387/000095017025059557/catx-20250429.htm)) |
| July 24, 2025 | [VIR-5525 trial start](https://sec-api.dev/pdufa/vir-5525) | VIR | Solid Tumors | completed | "On July 24, 2025, Vir Biotechnology, Inc. (the Company) issued a press release announcing the first patient dosed in the Company's Phase 1 clinical trial evaluating VIR-5525, an investigational dual-masked T-cell engager targeting EGFR (epidermal growth factor receptor)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1706431/000162828025035847/vir-20250724.htm)) |
| Q1 2026 | [SKB105 trial start](https://sec-api.dev/pdufa/skb105) | CBIO | solid tumors | scheduled | "•Kelun-Biotech plans to initiate a Phase 1/2 trial of CR-003 (SKB105) in Greater China in the first quarter of 2026, with proof-of-concept data expected in the first quarter of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1253689/000162828025055221/exhibit992-cbiopressrelease.htm)) |
| Q1 2026 | [Ivonescimab trial start](https://sec-api.dev/pdufa/ivonescimab) | CBIO | solid tumors | scheduled | "We are thrilled with the engagement from clinicians who share our enthusiasm for CR-001 and plan to commence our global Phase 1 trial in patients with solid tumors in the first quarter of 2026 with initial data anticipated later next year." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1253689/000162828025049865/pressrelease-q32025.htm)) |
| June 8, 2026 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Solid Tumors | completed | "NCT04123366 (Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-06-08 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04123366)) |
| 1H 2027 | [Biologics trial start](https://sec-api.dev/pdufa/biologics) | HCWB | solid tumors | scheduled | "Based on promising data seen in preclinical in-vitro and in-vivo studies conducted by HCW Biologics, Trimmune expects to initiate a Phase 1 clinical trial in China in the first half of 2027 to evaluate HCW11-006 in the treatment of solid tumors." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1828673/000119312526134934/hcwb-20251231.htm)) |
| Feb to May 2028 | [Krazati (adagrasib) topline data readout](https://sec-api.dev/pdufa/adagrasib) | BMY | Solid Tumors | scheduled | "NCT07415031 (A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-16 (ESTIMATED); Lead Sponsor Mirati Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07415031)) |
| February 2028 | [Krazati (adagrasib) primary completion](https://sec-api.dev/pdufa/adagrasib) | BMY | Solid Tumors | scheduled | "NCT07415031 (A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-16 (ESTIMATED); Lead Sponsor Mirati Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07415031)) |
| Aug to Nov 2028 | [Navlimetostat topline data readout](https://sec-api.dev/pdufa/navlimetostat) | BMY | Solid Tumors | scheduled | "NCT07492680 (A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08-15 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07492680)) |
| August 2028 | [Navlimetostat primary completion](https://sec-api.dev/pdufa/navlimetostat) | BMY | Solid Tumors | scheduled | "NCT07492680 (A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08-15 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07492680)) |
| Sep to Dec 2028 | [INCB161734 topline data readout](https://sec-api.dev/pdufa/incb161734) | INCY | Solid Tumors | scheduled | "NCT07522073 (A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-15 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07522073)) |
| September 2028 | [INCB161734 primary completion](https://sec-api.dev/pdufa/incb161734) | INCY | Solid Tumors | scheduled | "NCT07522073 (A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-15 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07522073)) |

## Drugs

- [PSV359](https://sec-api.dev/pdufa/psv359) (CATX)
- [VIR-5525](https://sec-api.dev/pdufa/vir-5525) (VIR)
- [SKB105](https://sec-api.dev/pdufa/skb105) (CBIO)
- [Ivonescimab](https://sec-api.dev/pdufa/ivonescimab) (SMMT)
- [KEYTRUDA® (pembrolizumab)](https://sec-api.dev/pdufa/pembrolizumab) (MRK)
- [Biologics](https://sec-api.dev/pdufa/biologics) (HCWB)
- [Krazati (adagrasib)](https://sec-api.dev/pdufa/adagrasib) (BMY)
- [Navlimetostat](https://sec-api.dev/pdufa/navlimetostat) (BMY)
- [INCB161734](https://sec-api.dev/pdufa/incb161734) (INCY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/solid-tumors.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "solid tumors FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/solid-tumors

```bibtex
@misc{secapidev_indications_solid_tumors_20261116,
  title        = {solid tumors FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/solid-tumors}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_solid_tumors_20261116","title":"solid tumors FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/solid-tumors","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
